Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors have?
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors has 130 citations in the OpenAlex counts ScholarIQ stores.
When was Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors published?
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors has 2009 year in the ScholarIQ index.
What is the open-access status of Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors?
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors has hybrid oa status in the ScholarIQ index.
What is the DOI of Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors?
The DOI for Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors is on the source record.
What is the PMID of Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors?
The PMID for Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors is on the source record.
What is the OpenAlex record for Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors?
The OpenAlex for Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors is on the source record.